Diag-Nose.io

Diag-Nose.io is on a mission to eliminate respiratory disease by decoding the airway’s molecular pathways.

Backed by

Stephen Ho

Richard Lipscombe

Carl Stubbings

Radar Ventures

Breakthrough Victoria

Specialty Physician Associates

Raised 2M SEED on February 4, 2025

About

Diag-Nose.io builds a platform combining machine learning and advanced proteomics to analyze nasal liquid biopsies collected with the ABEL Microsampler, enabling biomarker-based respiratory diagnostics and therapy matching.

Mission

Diag-Nose.io develops precision diagnostic and drug-discovery solutions for respiratory disease using its RhinoMAP™ platform. RhinoMAP™ combines machine learning (artificial intelligence) with advanced proteomics to enable precision-matched treatments based on patient-specific biological endotypes. The system uses the patented ABEL Microsampler™ to collect nasal liquid biopsy samples for comprehensive biomarker analysis. Insights from the platform are intended to identify disease progression, therapeutic responsiveness, and optimal treatment pathways. The company plans to use the seed funds to expand operations and R&D. Founded in 2020 and led by CEO Eldin Rostom, Diag-Nose.io is based in Seattle, WA.

Quick Facts

Founded

2020

Funding

SEED

Industry

Biotechnology, Health Care, Health Diagnostics, Medical

Team Size

1-10

Headquarters

Melbourne, Victoria, Australia

Careers

View Careers Page

Diag-Nose.io

https://jobs.ashbyhq.com/diag-nose

No open roles at this time.

Check their careers page for updates